KR970706260A - 이미다졸 유도체(imidazole derivative) - Google Patents

이미다졸 유도체(imidazole derivative)

Info

Publication number
KR970706260A
KR970706260A KR1019970701989A KR19970701989A KR970706260A KR 970706260 A KR970706260 A KR 970706260A KR 1019970701989 A KR1019970701989 A KR 1019970701989A KR 19970701989 A KR19970701989 A KR 19970701989A KR 970706260 A KR970706260 A KR 970706260A
Authority
KR
South Korea
Prior art keywords
dichlorophenylthio
carbon atoms
substituted
unsubstituted
isopropyl
Prior art date
Application number
KR1019970701989A
Other languages
English (en)
Other versions
KR100387157B1 (ko
Inventor
히로히꼬 스기모또
다미오 후지와라
Original Assignee
시오노 요시히꼬
시오노기 세이야꾸 가부시끼가이샤
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 시오노 요시히꼬, 시오노기 세이야꾸 가부시끼가이샤 filed Critical 시오노 요시히꼬
Publication of KR970706260A publication Critical patent/KR970706260A/ko
Application granted granted Critical
Publication of KR100387157B1 publication Critical patent/KR100387157B1/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C07D233/58—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/84—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Abstract

본 발명은 병인 바이러스인 HIV의 증식을 특이적으로 저해하는 작용을 가지고, 또한 독성이 낮은 화합물을 제공하는 것을 목적으로 한다.
본 발명은 식(Ⅰ):
(식 중, R1은 수소, 탄소수 1~20의 알킬, 탄소수 2~7의 알케닐, 탄소수 4~12의 시클로알킬알킬 등이고, R2는 탄소수 1~6의 알킬, 탄소수 1~6의 아실,히드록시이미노메틸, 히드라조메틸 또는
-(CH2)n-R4
(식 중, R4는 할로겐, 알콕시, 히드록시 등이고, n은 1~3의 정수)이고, R3는 치환 혹은 비치환의 탄소수 1~6의 알킬이고, X, Y는 각각 독립하여 수소, 탄소수 1~3의 알킬, 할로겐, 또는 니트로이고, Z는 S, SO, SO2또는 CH2를 나타낸다)로 표시되는 것을 특징으로 하는 이미다졸 유도체, 또는 그 염이다.

Description

이미다졸 유도체(IMIDAZOLE DERIVATIVE)
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (10)

  1. 식(I):
    (식 중, R1은 수소, 탄소수 1~20의 알킬, 탄소수 2~7의 알케닐, 탄소수 4~12의 시클로알킬알킬, 탄소수 1~6의 할로알킬, 탄소수 1~6의 옥소 알킬, 탄소수 8~13의 아로일알킬, 치환 혹은 비치환의 알랄킬, 치환 혹은 비치환의 헤테로아릴알킬, 치환 혹은 비치환의 카르바모일옥시알킬,카르바모일알킬옥시알킬 혹은 아실옥시알킬, 또는 분기상의 히드록시알킬이고, R2은 탄소수 1~6의 알킬, 탄소수 1~6의 아실, 히드록시이미노메틸, 히드라조메틸, 또는
    -(CH2)n-R4
    (식 중, R4는 할로겐, 알콕시, 히드록시, 시아노, 아실옥시, 아릴옥시카르보닐옥시, 알콕시카르보닐옥시, 카르복시, 치환 혹은 비치환의 카르바모일, 치환 혹은 비치환의 히드록시알킬옥시, 치환 혹은 비치환의 벤질옥시, 치환 혹은 비치환의 카르바모일옥시 혹은 티오카르바모일옥시, 치환 혹은 비치환의 아미노, 또는 아지드; n은 1~3의 정수)이고, R3은 치환 혹은 비치환의 탄소수 1~6의 알킬이고, X, Y는 각각 독립하여 수소, 탄소수 1~3의 알킬, 할로겐, 또는 니트로이고, Z는 S, SO, SO2또는 CH2를 나타낸다)로 표시되는 것을 특징으로 하는 이미다졸 유도체, 또는 그 염.
  2. 제1항에 있어서, 이미다졸 유도체가 식(I′):
    (식 중, R1,R2,R3,X,Y 및 Z는 상기한 바와 동일하다)인 것을 특징으로 하는 화합물.
  3. 제1항에 있어서, R1이 탄소수 1~6인 알킬, 탄소수 1~6의 히드록시알킬, 또는 피리딜메틸인 것을 특징으로 하는 화합물,
  4. 제1항에 있어서, R2가 -(CH2)nR4이고, R4가 히드록시 또는 카르바모일옥시인 것을 특징으로 하는 화합물.
  5. 제1항에 있어서, R3가 이소프로필인 것을 특징으로 하는 화합물.
  6. 제1항에 있어서, X 및 Y가 할로겐인 것을 특징으로 하는 화합물.
  7. 제1항에 있어서, Z가 S인 것을 특징으로 하는 화합물.
  8. 제1항에 있어서, 이미다졸 유도체가, (A-1)2-카르바모일옥시메틸-5-(3,5-디클로로페닐티오)-1-에틸-4-이소프로필-1H-이미다졸, (A-2) 2-[5-(3,5-디클로로페닐티오)-4-이소프로필-1-메틸-1H-이미다졸-2-일]에탄올, (A-3) 2-카르바모일옥시메틸-5-(3,5-디클로로페닐티오)-4-이소프로필-1-(피리딘-4-일)메틸-1H-이미다졸, (A-4) [5-(3,5-디클로로페닐티오)-1-에틸-4-이소프로필-1H-이미다졸-2-일]메탄올, (A-5) [1-(2-히드록시프로필)-5-(3,5-디클로로페닐티오-4-이소프로필-1H-이미다졸-2-일]메탄올, (A-6) [5-(3,5-디클로로페닐티오)-4-이소프로필-1-메틸-1H-이미다졸-2-일]아세트니트릴, (A-7) [5-(3,5-디클로로페닐티오)-1-(4-아미노벤질)-4-이소프로필-1H-이미다졸-2-일]메탄올, (A-8) [5-(3,5-디클로로페닐티오)-1-(3-아미노벤질)-4-이소프로필-1H-이미다졸-2-일]메탄올, (A-9) 2-[5-(3,5-디클로로페닐티오)-4-이소프로필-1-에틸-1H-이미다졸-2-일]에탄올, (A-10) 2-(2-(카르바모일옥시)에틸]-5-(3,5-디클로로페닐티오-1-에틸-4-이소프로필-1H-이미다졸, (A-11) [5-(3,5-디클로로페닐티오)-4-이소프로필-1-2(1H)-피리돈-5-일)메틸-1H-이미다졸-2-일]메탄올, (A-12) 2-카르바모일옥시메틸-5-(3,5-디클로로페닐티오)-1-(2(1H)-피리돈-5-일)메틸-4-이소프로필-1H-이미다졸인 것을 특징으로 하는 화합물.
  9. 청구항 1에 기재된 화합물을 유효성분으로 하는 것을 특징으로 하는 의약 조성물.
  10. 청구항 1에 기재된 화합물을 유효성분으로 하는 것을 특징으로 하는 항HIV제.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019970701989A 1994-09-26 1995-09-25 이미다졸유도체 KR100387157B1 (ko)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
JP25749094 1994-09-26
JP94-257490 1994-09-26
JP8469095 1995-03-15
JP95-84690 1995-03-15
JP95-227205 1995-08-12
JP22720595 1995-08-12

Publications (2)

Publication Number Publication Date
KR970706260A true KR970706260A (ko) 1997-11-03
KR100387157B1 KR100387157B1 (ko) 2003-09-29

Family

ID=27304632

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019970701989A KR100387157B1 (ko) 1994-09-26 1995-09-25 이미다졸유도체

Country Status (20)

Country Link
US (2) US5910506A (ko)
EP (1) EP0786455B1 (ko)
JP (1) JP3155009B2 (ko)
KR (1) KR100387157B1 (ko)
CN (1) CN1093535C (ko)
AT (1) ATE255564T1 (ko)
BR (1) BR9509024A (ko)
CA (1) CA2200316C (ko)
DE (1) DE69532245T2 (ko)
DK (1) DK0786455T3 (ko)
ES (1) ES2211917T3 (ko)
FI (1) FI971234A (ko)
HU (1) HUT77357A (ko)
MX (1) MX9702030A (ko)
NO (1) NO308739B1 (ko)
PL (1) PL183931B1 (ko)
PT (1) PT786455E (ko)
RU (1) RU2157368C2 (ko)
TW (1) TW401404B (ko)
WO (1) WO1996010019A1 (ko)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69732230T2 (de) * 1996-03-28 2005-12-22 Shionogi & Co., Ltd. Durch lymphe absorbierbare imidazolderivate
CN1111406C (zh) * 1996-04-04 2003-06-18 盐野义制药株式会社 含咪唑衍生物的抗hiv组合物
ES2245005T3 (es) * 1996-12-26 2005-12-16 SHIONOGI & CO., LTD. Procedimiento de produccion de derivados de imidazol.
AU7890398A (en) * 1996-12-26 1998-07-31 Shionogi & Co., Ltd. Process for the preparation of carbamoyllated imidazole derivatives
TWI232214B (en) 1998-04-16 2005-05-11 Shionogi & Co Preparation of aryl sulfenyl halide
EP1172097B1 (en) 1999-04-12 2004-09-08 Shionogi & Co., Ltd. Process for producing medicinal composition of a basic hydrophobic medicinal compound
GB0016787D0 (en) 2000-07-07 2000-08-30 Pfizer Ltd Compounds useful in therapy
RU2256657C2 (ru) 2001-01-31 2005-07-20 Уорнер-Ламберт Компани Ллс Способ карбамоилирования спиртов
EP1370539B1 (en) * 2001-02-23 2011-11-09 K.U. Leuven Research and Development Hiv inhibiting n-aminoimidazole derivatives
EA007184B1 (ru) 2001-04-10 2006-08-25 Пфайзер Инк. Производные пиразола для лечения инфекции вируса иммунодефицита человека (вич)
GB0113524D0 (en) * 2001-06-04 2001-07-25 Hoffmann La Roche Pyrazole derivatives
CA2481449A1 (en) 2002-04-26 2003-11-06 Gilead Sciences, Inc. Method and compositions for identifying anti-hiv therapeutic compounds
TW200423930A (en) 2003-02-18 2004-11-16 Hoffmann La Roche Non-nucleoside reverse transcriptase inhibitors
EP1608629A1 (en) 2003-03-24 2005-12-28 F. Hoffmann-La Roche Ag Benzyl-pyridazinons as reverse transcriptase inhibitors
US7427636B2 (en) 2003-04-25 2008-09-23 Gilead Sciences, Inc. Inosine monophosphate dehydrogenase inhibitory phosphonate compounds
US7407965B2 (en) 2003-04-25 2008-08-05 Gilead Sciences, Inc. Phosphonate analogs for treating metabolic diseases
EP1620109A2 (en) 2003-04-25 2006-02-01 Gilead Sciences, Inc. Kinase inhibitor phosphonate conjugates
NZ542342A (en) 2003-04-25 2009-05-31 Gilead Sciences Inc Antiviral phosphonate analogs
US7432261B2 (en) 2003-04-25 2008-10-07 Gilead Sciences, Inc. Anti-inflammatory phosphonate compounds
WO2005002626A2 (en) 2003-04-25 2005-01-13 Gilead Sciences, Inc. Therapeutic phosphonate compounds
US7470724B2 (en) 2003-04-25 2008-12-30 Gilead Sciences, Inc. Phosphonate compounds having immuno-modulatory activity
US7452901B2 (en) 2003-04-25 2008-11-18 Gilead Sciences, Inc. Anti-cancer phosphonate analogs
US7273716B2 (en) 2003-04-25 2007-09-25 Gilead Sciences, Inc. Methods and compositions for identifying therapeutic compounds with GS-7340 ester hydrolase
WO2004096285A2 (en) 2003-04-25 2004-11-11 Gilead Sciences, Inc. Anti-infective phosphonate conjugates
WO2005016912A1 (en) * 2003-08-19 2005-02-24 Pfizer Inc. An efficient microbial preparation of capravirine metabolites m4 and m5
WO2005044308A1 (en) 2003-10-24 2005-05-19 Gilead Sciences, Inc. Phosphonate analogs of antimetabolites
WO2005044279A1 (en) 2003-10-24 2005-05-19 Gilead Sciences, Inc. Purine nucleoside phosphonate conjugates
WO2005063751A1 (en) 2003-12-22 2005-07-14 Gilead Sciences, Inc. 4’-substituted carbovir-and abacavir-derivatives as well as related compounds with hiv and hcv antiviral activity
CA2562846A1 (en) * 2004-04-14 2005-10-27 Pfizer Inc. Sulphur-linked imidazole compounds for the treament of hiv
AU2005330489B2 (en) 2004-07-27 2011-08-25 Gilead Sciences, Inc. Nucleoside phosphonate conjugates as anti HIV agents
EP1798226A4 (en) * 2004-08-04 2009-06-17 Taisho Pharmaceutical Co Ltd TRAIZOL DERIVATIVE
CA2592909A1 (en) * 2005-01-06 2006-07-13 Pfizer Limited Imidazole derivatives as enzyme reverse transcriptase modulators
EP2311814A1 (en) * 2005-12-01 2011-04-20 F. Hoffmann-La Roche AG 2,4,5-triphenyl imidazoline derivatives as inhibitors of the interaction between P53 and MDM2 proteins for use as anticancer agents
EP1988083B1 (en) 2006-02-03 2014-04-02 Taisho Pharmaceutical Co., Ltd. Triazole derivative
JP5218737B2 (ja) * 2006-02-06 2013-06-26 大正製薬株式会社 スフィンゴシン−１−リン酸結合阻害物質
US7649098B2 (en) * 2006-02-24 2010-01-19 Lexicon Pharmaceuticals, Inc. Imidazole-based compounds, compositions comprising them and methods of their use
EP2005957B1 (en) 2006-03-31 2012-05-30 Takeda Pharmaceutical Company Limited Acid secretion inhibitor
PT2057125E (pt) 2006-08-16 2011-05-31 Hoffmann La Roche Inibidores n?o nucle?sidos de transcriptase inversa
PL2177512T3 (pl) 2007-08-01 2012-09-28 Taisho Pharmaceutical Co Ltd Inhibitor wiązania S1P1
TW200920355A (en) * 2007-09-06 2009-05-16 Lexicon Pharmaceuticals Inc Compositions and methods for treating immunological and inflammatory diseases and disorders
TW200920366A (en) * 2007-09-28 2009-05-16 Takeda Pharmaceutical 5-membered heterocyclic compound
KR101610415B1 (ko) 2007-12-21 2016-04-07 에프. 호프만-라 로슈 아게 헤테로사이클릭 항바이러스 화합물
WO2010005986A1 (en) 2008-07-08 2010-01-14 Gilead Sciences, Inc. Salts of hiv inhibitor compounds
TW201040168A (en) * 2009-02-12 2010-11-16 Exelixis Inc TGR5 agonists
JP5552481B2 (ja) 2009-03-26 2014-07-16 武田薬品工業株式会社 ピラゾール化合物
EP2508511A1 (en) 2011-04-07 2012-10-10 Laboratoire Biodim Inhibitors of viral replication, their process of preparation and their therapeutical uses
EP2890684B1 (en) * 2012-07-24 2018-02-14 Bial-Portela & CA, S.A. Urea compounds and their use as enzyme inhibitors
EP2716639A1 (en) 2012-10-05 2014-04-09 Laboratoire Biodim Inhibitors of viral replication, their process of preparation and their therapeutical uses
EP2716632A1 (en) 2012-10-05 2014-04-09 Laboratoire Biodim Inhibitors of viral replication, their process of preparation and their therapeutical uses
GB201602934D0 (en) 2016-02-19 2016-04-06 Cancer Res Inst Royal Compounds
EP3381905A1 (en) * 2017-03-30 2018-10-03 Institut National de la Sante et de la Recherche Medicale (INSERM) Novel antiviral compounds
SI3661937T1 (sl) 2017-08-01 2021-11-30 Gilead Sciences, Inc. Kristalinične oblike etil((S)-((((2R,5R)-5-(6-amino-9H-purin-9-IL)-4- fluoro-2,5-dihidrofuran-2-IL)oksi)metil)(fenoksi)fosforil)-L-alaninata (GS-9131) za zdravljenje virusnih okužb

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS63150266A (ja) * 1986-12-12 1988-06-22 Mitsui Petrochem Ind Ltd ベンジルイミダゾ−ル誘導体
JPH0283373A (ja) * 1988-05-19 1990-03-23 Nippon Soda Co Ltd ５員環の複素環化合物及びその製造方法
IL98319A (en) * 1990-07-05 1997-04-15 Roussel Uclaf Sulphurous derivatives of imidazole, their preparation process, and pharmaceutical compositions containing them
TW235963B (ko) * 1992-01-16 1994-12-11 Shionogi & Co
DE10230797C2 (de) * 2001-07-16 2003-09-25 Dieter Reif Befestigungsklammer zur Verbindung von Holzbauteilen

Also Published As

Publication number Publication date
WO1996010019A1 (fr) 1996-04-04
PT786455E (pt) 2004-02-27
BR9509024A (pt) 1997-09-30
EP0786455A1 (en) 1997-07-30
HUT77357A (hu) 1998-03-30
FI971234A (fi) 1997-05-23
AU706095B2 (en) 1999-06-10
DE69532245D1 (en) 2004-01-15
JP3155009B2 (ja) 2001-04-09
KR100387157B1 (ko) 2003-09-29
NO308739B1 (no) 2000-10-23
EP0786455A4 (en) 1998-12-30
US5910506A (en) 1999-06-08
NO971306L (no) 1997-05-21
DK0786455T3 (da) 2004-03-29
CA2200316A1 (en) 1996-04-04
CN1093535C (zh) 2002-10-30
FI971234A0 (fi) 1997-03-25
AU4788896A (en) 1996-04-19
CA2200316C (en) 2004-09-21
DE69532245T2 (de) 2004-09-16
RU2157368C2 (ru) 2000-10-10
MX9702030A (es) 1997-06-28
US6147097A (en) 2000-11-14
PL183931B1 (pl) 2002-08-30
NO971306D0 (no) 1997-03-20
CN1158609A (zh) 1997-09-03
ES2211917T3 (es) 2004-07-16
TW401404B (en) 2000-08-11
PL320009A1 (en) 1997-09-01
EP0786455B1 (en) 2003-12-03
ATE255564T1 (de) 2003-12-15

Similar Documents

Publication Publication Date Title
KR970706260A (ko) 이미다졸 유도체(imidazole derivative)
RU97106829A (ru) Производные имидазола
DE69021472T2 (de) Pyrazolderivate, Verfahren zu deren Herstellung und diese enthaltende pharmazeutische Zusammenstellung.
DE69230163T2 (de) Thiazolylbenzofuranderivate, Verfahren zu deren Herstellung und pharmazeutische Zusammensetzungen, die sie enthalten
KR970706274A (ko) 1,2,3,4-테트라하이드로퀴녹살린디온 유도체(1,2,3,4-Tetrahydroquinoxalinedione derivative)
RU99119545A (ru) Производные дитиолана, лекарственные средства
RU2008125158A (ru) Гетероциклические соединения, обладающие ингибирующей активностью по отношению к 11-гидроксистероиддегидрогеназе 1 типа
KR930019637A (ko) 비페닐설포닐우레아 또는 비페닐설포닐우레탄 측쇄를 갖는 이미다졸 유도체, 이의 제조방법 및 용도
KR900001688A (ko) 벤조디아제핀 유도체
KR960704884A (ko) 항종양제 또는 항바이러스제로서의 디스타마이신 A 동족체 (Distamycin A analogues as antitumour or antiviral agents)
KR880007536A (ko) 피롤로벤즈 이미다졸, 이들의 제조방법 및 이들을 함유하는 약리학적 조성물
KR900003127A (ko) 강심제
KR930006014A (ko) 삼환식 복소환식 화합물
KR920006322A (ko) 벤젠, 피리딘 및 피리미딘 유도체
RU99101341A (ru) 4-оксоциклические соединения мочевины, фармацевтическая композиция, способ лечения
RU2426734C2 (ru) Пиразолопиридины и их аналоги
KR930702980A (ko) 인단 유도체
KR940011450A (ko) 살진균성 2-알콕시-2-이미다졸린-5-온 유도체
HUT59124A (en) Process for producing 2-(aminoalkyl)-5-(arylalkyl)-1,3-dioxane derivatives and pharmaceutical compositions comprising such derivatives as active ingredient
KR970707122A (ko) 퀴놀린 유도체(quinoline derivative)
KR960037677A (ko) 4-인돌릴피페라지닐 유도체
KR900012925A (ko) 인돌 유도체
TNSN97086A1 (fr) La substitution des acides derivatives 4-albutyrique comme inhibiteurs de la matrice metalloprotease.
KR950702544A (ko) 비페닐메탄 유도체 및 이를 함유하는 약제
KR900014339A (ko) 헤테로시클릭 화합물, 그의 제조방법, 이를 함유하는 제약 조성물 및 의약으로서의 용도

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20060525

Year of fee payment: 4

LAPS Lapse due to unpaid annual fee